<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.1" specific-use="sps-1.9" article-type="research-article" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">ijcs</journal-id>
      <journal-title-group>
        <journal-title>International Journal of Cardiovascular Sciences</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Int J Cardiovasc Sci </abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2359-4802</issn>
      <issn pub-type="epub">2359-5647</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id specific-use="scielo-v3" pub-id-type="publisher-id">VWM5k4TYQZMp7jLnX6RpRpc</article-id>
      <article-id specific-use="scielo-v2" pub-id-type="publisher-id">S2359-56472023000100233</article-id>
      <article-id pub-id-type="other">00233</article-id>
      <article-id pub-id-type="doi">10.36660/ijcs.20220158</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>ORIGINAL ARTICLE</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Health Literacy, Patient Knowledge and Adherence to Oral Anticoagulation in Primary Care</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-4278-3771</contrib-id>
          <name>
            <surname>Marcolino</surname>
            <given-names>Milena Soriano</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>acquisition of data</role>
          <role>analysis and interpretation of the data and critical revision of the manuscript for intellectual content</role>
          <role>statistical analysis</role>
          <role>obtaining financing</role>
          <role>writing of the manuscript</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-1571-3850</contrib-id>
          <name>
            <surname>Sales</surname>
            <given-names>Tha&#237;s Lorenna Souza</given-names>
          </name>
          <role>acquisition of data</role>
          <role>analysis and interpretation of the data and critical revision of the manuscript for intellectual content</role>
          <role>statistical analysis</role>
          <role>writing of the manuscript</role>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-3116-4713</contrib-id>
          <name>
            <surname>Oliveira</surname>
            <given-names>Jo&#227;o Ant&#244;nio de</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>acquisition of data</role>
          <role>analysis and interpretation of the data and critical revision of the manuscript for intellectual content</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-6377-241X</contrib-id>
          <name>
            <surname>Rios</surname>
            <given-names>Danyelle Romana Alves</given-names>
          </name>
          <role>analysis and interpretation of the data and critical revision of the manuscript for intellectual content</role>
          <role>writing of the manuscript</role>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-0149-9731</contrib-id>
          <name>
            <surname>Pedroso</surname>
            <given-names>Tha&#237;s Marques</given-names>
          </name>
          <role>analysis and interpretation of the data and critical revision of the manuscript for intellectual content</role>
          <role>writing of the manuscript</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-0845-5814</contrib-id>
          <name>
            <surname>S&#225;</surname>
            <given-names>Laura Caetano de</given-names>
          </name>
          <role> analysis and interpretation of the data and critical revision of the manuscript for intellectual content</role>
          <role>writing of the manuscript</role>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-5211-411X</contrib-id>
          <name>
            <surname>Martins</surname>
            <given-names>Maria Auxiliadora</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>acquisition of data</role>
          <role>analysis and interpretation of the data and critical revision of the manuscript for intellectual content</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-2740-0042</contrib-id>
          <name>
            <surname>Ribeiro</surname>
            <given-names>Antonio Luiz Pinho</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>analysis and interpretation of the data and critical revision of the manuscript for intellectual content</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label> 1 </label>
        <institution content-type="orgname">Universidade Federal de Minas Gerais</institution>
        <addr-line>
          <named-content content-type="city">Belo Horizonte</named-content>
          <named-content content-type="state">MG</named-content>
        </addr-line>
        <country country="BR">Brazil</country>
        <institution content-type="original"> Universidade Federal de Minas Gerais , Belo Horizonte , MG &#8211; Brazil </institution>
      </aff>
      <aff id="aff2">
        <label> 2 </label>
        <institution content-type="orgname">Rede de Telessa&#250;de de Minas Gerais</institution>
        <addr-line>
          <named-content content-type="city">Belo Horizonte</named-content>
          <named-content content-type="state">MG</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original"> Rede de Telessa&#250;de de Minas Gerais , Belo Horizonte , MG - Brasil </institution>
      </aff>
      <aff id="aff3">
        <label> 3 </label>
        <institution content-type="orgname">Universidade Federal de S&#227;o Jo&#227;o del-Rei</institution>
        <addr-line>
          <named-content content-type="city">S&#227;o Jo&#227;o del-Rei</named-content>
          <named-content content-type="state">MG</named-content>
        </addr-line>
        <country country="BR">Brazil</country>
        <institution content-type="original"> Universidade Federal de S&#227;o Jo&#227;o del-Rei , S&#227;o Jo&#227;o del-Rei , MG &#8211; Brazil </institution>
      </aff>
      <aff id="aff4">
        <label> 4 </label>
        <institution content-type="orgname">Faculdade Ci&#234;ncias M&#233;dicas de Minas Gerais</institution>
        <addr-line>
          <named-content content-type="city">Belo Horizonte</named-content>
          <named-content content-type="state">MG</named-content>
        </addr-line>
        <country country="BR">Brazil</country>
        <institution content-type="original"> Faculdade Ci&#234;ncias M&#233;dicas de Minas Gerais , Belo Horizonte , MG &#8211; Brazil </institution>
      </aff>
      <author-notes>
        <corresp id="c01">Mailing Address: Tha&#237;s Marques Pedroso Universidade Federal de Minas Gerais. Avenida Professor Alfredo Balena, 190, room 246. Postal code: 31270-901. Belo Horizonte, MG &#8211; Brazil E-mail: <email>milenamarc@gmail.com</email> </corresp>
        <fn fn-type="conflict">
          <p>Potential Conflict of Interest</p>
          <p>No potential conflict of interest relevant to this article was reported.</p>
        </fn>
      </author-notes>
      <pub-date date-type="pub" publication-format="electronic">
        <day>25</day>
        <month>08</month>
        <year>2023</year>
      </pub-date>
      <pub-date date-type="collection" publication-format="electronic">
        <year>2023</year>
      </pub-date>
      <volume>36</volume>
      <elocation-id>e20220158</elocation-id>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>09</month>
          <year>2022</year>
        </date>
        <date date-type="rev-recd">
          <day>16</day>
          <month>02</month>
          <year>2023</year>
        </date>
        <date date-type="accepted">
          <day>07</day>
          <month>04</month>
          <year>2023</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/" xml:lang="en">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <title>Abstract</title>
        <sec>
          <title>Background</title>
          <p>Warfarin is the only oral anticoagulant available in the Brazilian public health system. Health knowledge and treatment are essential to achieving the desirable therapeutic effect. However, data on these aspects among primary care patients are still lacking.</p>
        </sec>
        <sec>
          <title>Objective</title>
          <p>To assess health literacy, patient knowledge, and adherence to oral anticoagulation with warfarin, as well as the medication regimen complexity in primary health units in the municipality of Divin&#243;polis, Minas Gerais, Brazil.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>This cross-sectional study included patients using warfarin from primary care settings. Sociodemographic and clinical data were collected from medical records. Short Assessment of Health Literacy for Portuguese-Speaking Adults (SAHLPA-18), Oral Anticoagulation Knowledge (OAK), adaptation of the Measure of Adherence to Treatment (MAT-adapted) to oral anticoagulation, and Medication Regimen Complexity Index (MRCI) were applied, and the time in therapeutic range (TTR) was calculated. Patients were stratified in two groups (TTR &lt; 60% and TTR &#8805; 60%) and compared using Fisher's exact test at a significance level of p &lt; 0.050.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>Analysis included 162 patients (64.8 &#177; 12.7 years old, 55.6% women). Nonvalvular atrial fibrillation (26.5%) and venous thromboembolism (24.1%) were the main indications for warfarin, and 67.9%, 88.3%, and 16.7% of the patients had inadequate health literacy, insufficient knowledge regarding anticoagulant therapy, and non-adherence to warfarin therapy, respectively. There was no significant association of these parameters in relation to TTR. MRCI showed high pharmacotherapy complexity between the drug prescriptions.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>This study showed alarming insufficient knowledge about warfarin therapy and low health literacy in primary care patients.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Anticoagulants</kwd>
        <kwd>Warfarin</kwd>
        <kwd>Primary Health Care</kwd>
        <kwd>Cardiovascular Diseases</kwd>
        <kwd>Health Literacy</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>CNPq</funding-source>
          <award-id>465518/2014-1</award-id>
        </award-group>
        <award-group>
          <funding-source>CNPq</funding-source>
          <award-id>428433/2016-2</award-id>
        </award-group>
        <award-group>
          <funding-source>FAPEMIG</funding-source>
          <award-id>RED-00081-16</award-id>
        </award-group>
        <award-group>
          <funding-source>CNPq</funding-source>
          <award-id>310790/2021-2</award-id>
        </award-group>
        <award-group>
          <funding-source>FAPEMIG</funding-source>
          <award-id>PPM-00428-17</award-id>
        </award-group>
        <award-group>
          <funding-source>FAPEMIG</funding-source>
          <award-id>RED-00081-16</award-id>
        </award-group>
        <award-group>
          <funding-source>FAPEMIG</funding-source>
          <award-id>310561/2021-3</award-id>
        </award-group>
        <award-group>
          <funding-source>CNPq</funding-source>
          <award-id>103315/2021-7</award-id>
        </award-group>
        <award-group>
          <funding-source>University of Minas Gerais</funding-source>
          <award-id>88887.142558/2017-00</award-id>
        </award-group>
        <award-group>
          <funding-source>CAPES</funding-source>
          <award-id>001</award-id>
        </award-group>
        <funding-statement>Sources of Funding: This study was supported by the National Institute of Science and Technology for Health Technology Assessment (IATS/CNPq, grant 465518/2014-1) and National Council for Scientific and Technological Development (CNPq, grant 428433/2016-2) and Minas Gerais State Agency for Research and Development (FAPEMIG, grant RED-00081-16). Ribeiro ALP was supported in part by the Brazilian research agencies CNPq (Bolsa de Produtividade em Pesquisa 310790/2021-2) and FAPEMIG (Programa Pesquisador Mineiro PPM-00428-17 and Rede de Teleassist&#234;ncia de Minas Gerais RED-00081-16), and Marcolino MS was supported in part by CNPq (Bolsa de Produtividade em Pesquisa 310561/2021-3). Ribeiro ALP and Marcolino MS are members of the National Institute of Science and Technology for Health Technology. S&#225; LC received a scholarship from CNPq (IATS/CNPq, grant 103315/2021-7), Pedroso TM received scholarships from Pr&#243;-Reitoria de Extens&#227;o from Federal University of Minas Gerais (PROEX UFMG) and Oliveira JAQ received doctoral grant (number 88887.142558/2017-00) from the Coordena&#231;&#227;o de Aperfei&#231;oamento de Pessoal de N&#237;vel Superior - Brasil (CAPES) &#8211; Finance Code 001, as part of the IATS/CNPq.</funding-statement>
      </funding-group>
      <counts>
        <fig-count count="0"/>
        <table-count count="3"/>
        <equation-count count="0"/>
        <ref-count count="49"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>For more than half a century, oral anticoagulants have been used for the treatment and primary and secondary prevention of venous and arterial thromboembolic events in patients with atrial fibrillation, mechanical heart valves prosthesis, after acute myocardial infarction, treatment of antiphospholipid antibody, among others. <sup><xref rid="B1" ref-type="bibr">1</xref></sup> Warfarin is one of the most prescribed anticoagulants in history, and, despite the advent of direct oral anticoagulants (DOACs), it is still frequently used in clinical practice. <sup><xref rid="B2" ref-type="bibr">2</xref> , <xref rid="B3" ref-type="bibr">3</xref> </sup> In Brazil, it is the most used oral anticoagulant in the public health system. <sup><xref rid="B4" ref-type="bibr">4</xref></sup> This scenario is due to the high direct costs of the DOACs, despite the fact that a previous study has shown that, in the Brazilian context, the cumulative costs per patient using warfarin with follow-up in anticoagulation clinics is currently higher than the strategy of prescribing the new oral anticoagulants. <sup><xref rid="B5" ref-type="bibr">5</xref></sup> Furthermore, there is a lack of proven efficacy and safety of DOACs for patients with Chagas disease and mechanical heart valves prosthesis. <sup><xref rid="B6" ref-type="bibr">6</xref></sup> </p>
      <p>Anticoagulation with warfarin is quite challenging due to the narrow therapeutic index, high half-life value, various food and drug interactions, genetic variations, body mass index, age, adherence, and patient knowledge about oral anticoagulation that can affect its efficacy and safety, requiring rigorous therapeutic monitoring through the International Normalized Ratio (INR) to guide dose adjustment and avoid adverse effects. <sup><xref rid="B7" ref-type="bibr">7</xref> - <xref rid="B11" ref-type="bibr">11</xref> </sup> The non-adherence or the lack of knowledge about warfarin treatment is a contributor to poor quality of treatment, which increases the risk of bleeding and thromboembolic events, <sup><xref rid="B11" ref-type="bibr">11</xref></sup> elevating the costs associated with hospitalizations due to the warfarin adverse events. <sup><xref rid="B12" ref-type="bibr">12</xref></sup> Additionally, it is highlighted that medication adherence and other health outcomes, such as hospitalization, hospital readmission, and emergency room visit may be influenced by medication regimen complexity, assessed by the Medication Regimen Complexity Index (MRCI). <sup><xref rid="B13" ref-type="bibr">13</xref></sup> </p>
      <p>In this context, health literacy, patient knowledge, and adherence to oral anticoagulation are essential to achieve the desirable therapeutic effect with reduced incidence of adverse drug events. <sup><xref rid="B14" ref-type="bibr">14</xref> - <xref rid="B16" ref-type="bibr">16</xref> </sup> Costa et al. (2019) observed that educational interventions can contribute to the effectiveness and safety of oral anticoagulation therapy and improve the understanding and adherence of patients on warfarin treatment, favoring the achievement of better therapeutic results and the prevention of adverse events related to pharmacotherapy. <sup><xref rid="B17" ref-type="bibr">17</xref></sup> Moreover, the literature has emphasized the need to characterize the factors that influence medication regimen complexity through validated instruments. <sup><xref rid="B6" ref-type="bibr">6</xref></sup> Thus, the assessment of the mentioned aspects is the initial step towards improving the quality of anticoagulant therapy. However, information about these parameters in clinical practice, especially outside clinical trials, is still scarce. Therefore, our aim was to assess health literacy, patient knowledge, and adherence to oral anticoagulation with warfarin, as well as the medication regimen complexity in primary health units in the municipality of Divin&#243;polis, Minas Gerais.</p>
    </sec>
    <sec sec-type="methods">
      <title>Methods</title>
      <p>This cross-sectional study is part of the investigation named Anticoagula Divin&#243;polis Project, a quasi-experimental study which intends to implement a computerized decision support system to assist anticoagulation control in primary care in Divin&#243;polis, Minas Gerais, Southeast Brazil. This city has an estimated population of 242,505 inhabitants. <sup><xref rid="B18" ref-type="bibr">18</xref></sup> Primary care in Divin&#243;polis is organized in 43 primary care units. There were no protocols defined for monitoring patients on anticoagulant therapy in the city. Patients on warfarin were frequently referred for secondary care or sought service in the private system. The present study focused on baseline assessment for the Anticoagula Divin&#243;polis Project.</p>
      <sec>
        <title>Study patients and procedures</title>
        <p>Primary care facilities which had more than 2 patients on anticoagulation control were included in this study. All patients aged 18 years or older on oral anticoagulation with warfarin being monitored at those facilities were eligible. They were recruited from May 1, 2018 to February 28, 2020 and identified through an active search in the waiting rooms at the primary care centers. Prescriptions were dispensed at the municipal district&#8217;s health units, and INR results were obtained in the public system.</p>
        <p>Data collection was performed by trained pharmacists who were members of the study team. These professionals were properly trained to apply validated tests and review the medical records. The study included patients who met the eligibility criteria, agreed to participate in the study, and signed the informed consent form.</p>
        <p>The following validated tests were applied: (i) oral anticoagulation knowledge (OAK), to assess the knowledge of patients using warfarin regarding oral anticoagulation therapy; <sup><xref rid="B19" ref-type="bibr">19</xref></sup> (ii) adapted Measure of Adherence to Treatment (MAT-adapted) to oral anticoagulation, an instrument designed to measure patient adherence to oral anticoagulation therapy with warfarin; <sup><xref rid="B20" ref-type="bibr">20</xref></sup> (iii) Short Assessment of Health Literacy for Portuguese-Speaking Adults (SAHLPA-18), which aims to assess the ability to pronounce and understand common medical terms, thus verifying the level of health literacy; <sup><xref rid="B21" ref-type="bibr">21</xref></sup> and (iv) MRCI. <sup><xref rid="B22" ref-type="bibr">22</xref></sup> This instrument is capable of measuring the complexity of pharmacotherapy from the analysis of prescriptions, taking into consideration aspects such as the number of prescribed drugs, dosage forms, dose frequency, and instructions on necessary care during administration. <sup><xref rid="B22" ref-type="bibr">22</xref></sup> </p>
        <p>Data from 6 months prior to patient recruitment up to February 2020 were collected from paper and electronic medical records. The charts were reviewed to obtain information about clinical data, medications in use, and information on anticoagulation treatment (indication for anticoagulation, therapeutic target, INR results, and hemorrhagic risk). To obtain information on thromboembolic risk and hemorrhagic risk, we planned to collect data related to CHA <sub>2</sub> DS <sub>2</sub> -VASc and HAS-BLED scores. <sup><xref rid="B23" ref-type="bibr">23</xref></sup> However, given the absence of data on these scores, we performed the estimation of the bleeding risk based on the following risk factors present on the medical records: hypertension, abnormal renal/liver function, stroke history, age &gt; 65 years, and alcohol use. <sup><xref rid="B23" ref-type="bibr">23</xref></sup> </p>
      </sec>
      <sec>
        <title>Statistical analysis</title>
        <p>Categorical variables were reported as counts and percentages; continuous variables were reported as mean and standard deviation (SD) or median with interquartile range (IQR), as appropriate. The Kolmogorov-Smirnov test was applied to verify data normality.</p>
        <p>Regarding the test scales applied to the patients under study, the SAHLPA-18 score ranges from 0 to 50, and inadequate health literacy is characterized as fewer than 15 correct answers. The OAK score ranges from 0 to 20, and insufficient knowledge is considered as fewer than 15 points (75%). The MAT-adapted score ranges from 1 to 6. Values 5 and 6 are computed as 1, meaning the patient is adhering to the treatment. On the other hand, values from 1 to 4 are computed as 0, indicating non-adherent patients. The MRCI is based on the analysis of drug prescriptions, and the cut-off for high complexity pharmacotherapy is equal to or greater than 13.5. <sup><xref rid="B24" ref-type="bibr">24</xref></sup> </p>
        <p>Additionally, time in therapeutic range (TTR) was calculated using the Rosendaal method, <sup><xref rid="B25" ref-type="bibr">25</xref></sup> based on all INRs available from each patient from January 1, 2018 to March 15, 2020. TTR was used as a parameter to investigate anticoagulation control. Follow-up time was determined by the interval between the first recorded INR value (or the date of recruitment of the patient into the study, in cases of absence of an INR value or consultation record with anticoagulation information) and the end of the collection period of INR data (March 15, 2020), except for patients who died, who were permanently suspended from warfarin, or who dropped out of the study.</p>
        <p>Patients were stratified according to TTR (TTR &lt; 60% and TTR &#8805; 60%), and proportions were compared using Fisher&#8217;s exact test. Results were considered statistically significant at a significance level of p &lt; 0.050. IBM SPSS statistics software for Windows, version 20.0 (2011 release; IBM Corporation, Armonk, NY, USA) was used for statistical analyses.</p>
      </sec>
      <sec>
        <title>Ethics approval</title>
        <p>The study was approved by the Research Ethics Committee of the Federal University of Minas Gerais (CAAE 86822518.0.0000.5149), and it was conducted in accordance with the Helsinki Declaration. All participants provided written informed consent for their participation in the study.</p>
      </sec>
    </sec>
    <sec sec-type="results">
      <title>Results</title>
      <p>Overall, 188 patients were eligible for the study. Of these, 26 died before recruitment, and 162 were included in the analysis (mean age 64.8 &#177; 12.7 years old, 55.6% women) ( <xref rid="t1" ref-type="table">Table 1</xref> ).</p>
      <p>
        <table-wrap id="t1">
          <label>Table 1</label>
          <caption>
            <title>&#8211; Sociodemographic characteristics of included patients (n = 162)</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup>
              <col/>
              <col/>
            </colgroup>
            <thead>
              <tr>
                <th align="left">Characteristics</th>
                <th>N (%)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>
                  <bold>Age (years, on recruitment), (mean &#177; SD)</bold>
                </td>
                <td align="center">64.8 &#177; 12.7</td>
              </tr>
              <tr>
                <td> &#8805; 65 years</td>
                <td align="center">87 (53.7)</td>
              </tr>
              <tr>
                <td>
                  <bold>Female</bold>
                </td>
                <td align="center">90 (55.6)</td>
              </tr>
              <tr>
                <td> Family income</td>
                <td> </td>
              </tr>
              <tr>
                <td> Up to 1 minimum wage*</td>
                <td align="center">88 (54.3)</td>
              </tr>
              <tr>
                <td> 1 to 2 minimum wages*</td>
                <td align="center">26 (16)</td>
              </tr>
              <tr>
                <td> 2 to 4 minimum wages*</td>
                <td align="center">9 (5.6)</td>
              </tr>
              <tr>
                <td> 4 to 10 minimum wages*</td>
                <td align="center">1 (0.6)</td>
              </tr>
              <tr>
                <td> No income</td>
                <td align="center">19 (11.7)</td>
              </tr>
              <tr>
                <td> No information</td>
                <td align="center">19 (11.7)</td>
              </tr>
              <tr>
                <td colspan="2">
                  <bold>Education</bold>
                </td>
              </tr>
              <tr>
                <td> Illiterate</td>
                <td align="center">18 (11.1)</td>
              </tr>
              <tr>
                <td> Complete elementary school (8 years)</td>
                <td align="center">12 (7.4)</td>
              </tr>
              <tr>
                <td> Incomplete elementary school (1-8 years)</td>
                <td align="center">85 (52.5)</td>
              </tr>
              <tr>
                <td> Complete high school</td>
                <td align="center">15 (9.3)</td>
              </tr>
              <tr>
                <td> Incomplete high school</td>
                <td align="center">7 (4.3)</td>
              </tr>
              <tr>
                <td> Complete higher education</td>
                <td align="center">5 (3.1)</td>
              </tr>
              <tr>
                <td> Incomplete higher education</td>
                <td align="center">5 (3.1)</td>
              </tr>
              <tr>
                <td> No information</td>
                <td align="center">15 (9.3)</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="TFN1">
              <p>SD: standard deviation. Values shown are n (%) unless otherwise noted. *Minimum wage: BRL 998.00 (2019), which corresponded at that time to USD 257.88. <sup><xref rid="B48" ref-type="bibr">48</xref> , <xref rid="B49" ref-type="bibr">49</xref> </sup> </p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </p>
      <p>The median time of warfarin use by study patients was 4.2 (IQR 2.2 to 8.7) years. The main indications for oral anticoagulation with warfarin were nonvalvular atrial fibrillation (26.5%) and venous thromboembolism (24.1%). In 13.6% of the patients, the reason for anticoagulation was not registered. Most patients showed moderate hemorrhagic risk (68.5%). The median of INR values was 4.0 (IQR 1.0 to 8.0) per patient. The mean TTR was 44.0% (SD 28.7%), determined with data from 117 patients. <xref rid="t2" ref-type="table">Table 2</xref> shows the other clinical characteristics.</p>
      <p>
        <table-wrap id="t2">
          <label>Table 2</label>
          <caption>
            <title>&#8211; Clinical characteristics of included patients (n = 162)</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup>
              <col/>
              <col/>
            </colgroup>
            <thead>
              <tr>
                <th align="left">Characteristics</th>
                <th align="left">N (%)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td colspan="2">
                  <bold>Comorbidities</bold>
                </td>
              </tr>
              <tr>
                <td> Systemic arterial hypertension</td>
                <td>118 (72.8)</td>
              </tr>
              <tr>
                <td> Dyslipidemia</td>
                <td>65 (40.1)</td>
              </tr>
              <tr>
                <td> Diabetes mellitus</td>
                <td>40 (24.7)</td>
              </tr>
              <tr>
                <td> Hypothyroidism</td>
                <td>29 (17.9)</td>
              </tr>
              <tr>
                <td> Systolic heart failure</td>
                <td>28 (17.3)</td>
              </tr>
              <tr>
                <td> Hematological disease</td>
                <td>5 (3.1)</td>
              </tr>
              <tr>
                <td> Hyperthyroidism</td>
                <td>3 (1.9)</td>
              </tr>
              <tr>
                <td> Coronary artery disease</td>
                <td>2 (1.2)</td>
              </tr>
              <tr>
                <td> Liver disease</td>
                <td>2 (1.2)</td>
              </tr>
              <tr>
                <td> Neurological disease</td>
                <td>2 (1.2)</td>
              </tr>
              <tr>
                <td> Kidney disease</td>
                <td>2 (1.2)</td>
              </tr>
              <tr>
                <td> Peripheral arterial disease</td>
                <td>1 (0.6)</td>
              </tr>
              <tr>
                <td> Active neoplasm</td>
                <td>1 (0.6)</td>
              </tr>
              <tr>
                <td colspan="2">
                  <bold>Main indication for anticoagulation</bold>
                </td>
              </tr>
              <tr>
                <td> Non-valvular atrial fibrillation/flutter</td>
                <td>43 (26.5)</td>
              </tr>
              <tr>
                <td> Venous thromboembolism</td>
                <td>39 (24.1)</td>
              </tr>
              <tr>
                <td> Mechanical valve prosthesis</td>
                <td>30 (18.5)</td>
              </tr>
              <tr>
                <td> Valvular atrial fibrillation/flutter</td>
                <td>14 (8.6)</td>
              </tr>
              <tr>
                <td> Acute myocardial infarction</td>
                <td>4 (2.5)</td>
              </tr>
              <tr>
                <td> Ischemic stroke</td>
                <td>3 (1.9)</td>
              </tr>
              <tr>
                <td> Pulmonary hypertension</td>
                <td>3 (1.9)</td>
              </tr>
              <tr>
                <td> Valvulopathy</td>
                <td>2 (1.2)</td>
              </tr>
              <tr>
                <td> Biological valve prosthesis</td>
                <td>1 (0.6)</td>
              </tr>
              <tr>
                <td> Antiphospholipid antibody syndrome</td>
                <td>1 (0.6)</td>
              </tr>
              <tr>
                <td> Unidentified</td>
                <td>22 (13.6)</td>
              </tr>
              <tr>
                <td colspan="2">
                  <bold>INR therapeutic target</bold>
                </td>
              </tr>
              <tr>
                <td> 2.0 to 3.0</td>
                <td>132 (81.5)</td>
              </tr>
              <tr>
                <td> 2.5 to 3.5</td>
                <td>20 (12.3)</td>
              </tr>
              <tr>
                <td> Others&#8224;</td>
                <td>5 (3.1)</td>
              </tr>
              <tr>
                <td> Not registered</td>
                <td>5 (3.1)</td>
              </tr>
              <tr>
                <td colspan="2">
                  <bold>Bleeding risk&#8225;</bold>
                </td>
              </tr>
              <tr>
                <td> High</td>
                <td>15 (9.3)</td>
              </tr>
              <tr>
                <td> Moderate</td>
                <td>111 (68.5)</td>
              </tr>
              <tr>
                <td> Low</td>
                <td>36 (22.2)</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="TFN2">
              <p>INR: international normalized ratio. &#8224; Other therapeutic targets for INR were: 2.0 to 3.5 (n = 2), 2.5 to 3.0 (n = 2), and 3.0 to 4.0 (n = 1). &#8225; The risk may be underestimated due to the lack of information about the presence/absence of risk factors for the HAS-BLED score in the medical records of the included patients.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </p>
      <p>SAHLPA-18 results indicated that 67.9% of patients had fewer than 15 correct answers. Analysis of OAK demonstrated that 88.3% had less than 75% of correct answers. The MAT-adapted indicated that 16.7% presented non-adherence to warfarin therapy. There was no significant association when comparing the variables of interest between groups with different TTR ranges ( <xref rid="t3" ref-type="table">Table 3</xref> ). Additionally, it was possible to evaluate the MRCI of 151 patients, obtaining a median of 15.0 (IQR 10.0 to 19.0) points, which denotes high complexity in the medication.</p>
      <p>
        <table-wrap id="t3">
          <label>Table 3</label>
          <caption>
            <title>&#8211; Health literacy, patient knowledge, and adherence to warfarin therapy stratified by TTR range</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup>
              <col/>
              <col/>
              <col/>
              <col/>
              <col/>
            </colgroup>
            <thead>
              <tr>
                <th align="left">Variables</th>
                <th>Total (n = 162)</th>
                <th>TTR &lt; 60% (n = 82)*</th>
                <th>TTR &#8805; 60% (n = 35)*</th>
                <th>p-value <sup>&#8224;</sup> </th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>SAHLPA-18 (&lt; 15, inadequate)</td>
                <td align="center">110 (67.9)</td>
                <td align="center">59 (72.0)</td>
                <td align="center">23 (65.7)</td>
                <td align="center">0.515</td>
              </tr>
              <tr>
                <td>OAK (&lt; 75%, inadequate knowledge)</td>
                <td align="center">143 (88.3%)</td>
                <td align="center">72 (87.8%)</td>
                <td align="center">32 (91.4%)</td>
                <td align="center">0.752</td>
              </tr>
              <tr>
                <td>MAT (1 to 4, non-adherence)</td>
                <td align="center">27 (16.7%)</td>
                <td align="center">17 (20.7%)</td>
                <td align="center">6 (17.1%)</td>
                <td align="center">0.789</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="TFN3">
              <p>MAT: Measure of Adherence to Treatment; OAK: Oral Anticoagulation Knowledge; SAHLPA-18: Short Assessment of Health Literacy for Portuguese-Speaking Adults; TTR: time in therapeutic range. &#8224; Comparison of groups stratified by TTR using Fisher's exact test. * As TTR requires at least 2 INR measures to be calculated, it was only possible to be obtained in 117 patients.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </p>
      <p>The median follow-up time of the 162 patients was 16.5 (IQR 10.9 to 21.0) months. After recruitment up to March 2020, there were 16 (9.8%) deaths due to non-traumatic causes, 4 of them possibly related to anticoagulation (2 with hemorrhage and 2 with thromboembolism), and 10 patients withdrew from participating (1.9%) or had anticoagulation permanently suspended (4.3%).</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>This study provides the profile of patients on oral anticoagulation with warfarin in primary health units in Minas Gerais. As expected, atrial fibrillation and venous thromboembolism were the most frequent indications for anticoagulation. Lack of essential clinical information was identified in the medical records, such as indication for anticoagulation, therapeutic target, or even INR results and patient care plan. SAHLPA-18 indicated inadequate health literacy in 67.9% of the patients; OAK results suggested that 88.3% showed insufficient knowledge regarding anticoagulant therapy, and MAT-adapted indicated that 16.7% presented non-adherence to warfarin therapy. There was no significant association of these parameters in relation to TTR. MRCI showed high pharmacotherapy complexity between the drug prescriptions.</p>
      <p>Evidence demonstrates that health literacy is essential for improving health outcomes. Inadequate health literacy is clearly associated with an increased number of emergency visits, hospitalizations, and mortality. <sup><xref rid="B26" ref-type="bibr">26</xref></sup> Thus, as proper conditions for health literacy are ensured, patients become able to manage their own health status. <sup><xref rid="B27" ref-type="bibr">27</xref></sup> Observational studies carried out in Spain and the United States indicate that a higher level of health literacy results in better anticoagulation control. <sup><xref rid="B28" ref-type="bibr">28</xref> , <xref rid="B29" ref-type="bibr">29</xref> </sup> Martins et al. (2017) and Bartolazzi et al. (2021) demonstrated high prevalence of inadequate health literacy in Brazilian patients on warfarin therapy after application of SAHLPA-18 (72.3% and 79.0%, respectively), corroborating our findings. <sup><xref rid="B30" ref-type="bibr">30</xref> , <xref rid="B31" ref-type="bibr">31</xref> </sup> </p>
      <p>Another determining factor for anticoagulation control is the patient's knowledge of warfarin therapy. More than 88.0% of the patients enrolled in the study had insufficient OAK. This is not an uncommon finding in the literature, since other investigations related to oral anticoagulation showed that 68.1% to 85.1% of patients had insufficient knowledge about the therapy. <sup><xref rid="B32" ref-type="bibr">32</xref> , <xref rid="B33" ref-type="bibr">33</xref> </sup> In this regard, it is notable that the lack of understanding of the treatment may compromise the safe and effective use of warfarin, mainly due to its narrow therapeutic index. <sup><xref rid="B23" ref-type="bibr">23</xref></sup> </p>
      <p>It should be noted that low health literacy was a decisive factor for our results of insufficient knowledge about oral anticoagulation. Fang et al. (2006), Oramasionwu et al. (2014), and Rolls et al. (2017) demonstrated that patients with inadequate health literacy were less likely to correctly answer warfarin-related knowledge questions. <sup><xref rid="B29" ref-type="bibr">29</xref> , <xref rid="B34" ref-type="bibr">34</xref> , <xref rid="B35" ref-type="bibr">35</xref> </sup> In addition, 52.5% of study patients reported fewer than 8 years of schooling, and 11.1% were illiterate, which also contributed to the results obtained in the OAK. In general, patients are unaware of the reason for warfarin indication, the management of missed doses, food and drug interactions, and the possible consequences related to hypo- or hypercoagulation. <sup><xref rid="B36" ref-type="bibr">36</xref></sup> Therefore, the implementation of health education programs is fundamental to optimize the therapeutic results of oral anticoagulation with warfarin, especially in places with lower levels of education.</p>
      <p>It is essential to understand the reasons for treatment, since a well-informed patient, who is included in medical decisions, responds better to treatment. <sup><xref rid="B37" ref-type="bibr">37</xref> , <xref rid="B38" ref-type="bibr">38</xref> </sup> Based on the experience obtained during the development of the study in the primary health units of Divin&#243;polis, it is possible to affirm that education strategies aimed at training patients and the health team would be able to improve the doctor-patient relationship through shared decision-making processes and, thus, optimize anticoagulation control. <sup><xref rid="B39" ref-type="bibr">39</xref></sup> In the Brazilian Unified Health System (SUS), primary care is responsible for the management of chronic conditions, non-complex acute cases, prevention, and health promotion. That said, primary care is fully capable of managing patients using oral anticoagulants, but it is necessary to establish communication with an explicit system responsible for both care and individualized knowledge of the case, along with continuing education. The present study points to the urgent need for continuing education of physicians, nurses, and pharmacists to avoid worse results in clinical practice than those observed in clinical trials of oral anticoagulants.</p>
      <p>Although the study patients scored low on the SAHLPA-18 and the OAK, the results of the MAT-adapted surprisingly suggest a high percentage of treatment adherence (83.3%). Adherence to warfarin treatment is a very important factor for anticoagulation control; however, this has not been demonstrated by comparing different TTR ranges. As such high adherence is not usually related to low levels of education and health literacy as well as poor socioeconomic conditions, it is possible that the accuracy of the test to detect actual adherence to warfarin treatment has significant limitations. In this sense, the self-reported questionnaire may have overestimated adherence, since a single positive answer from the patient qualifies as adherence to the treatment. <sup><xref rid="B40" ref-type="bibr">40</xref></sup> A possible explanation for these results is the social desirability, which leads patients to provide desirable answers, even if they are not true, to avoid a critical response from the health professional. It is also plausible that the results were affected by the Hawthorne effect, a phenomenon in which patients aware of their participation in a study actively change their behavior towards positive results. <sup><xref rid="B41" ref-type="bibr">41</xref></sup> Therefore, future studies may use at least two measures of adherence, such as pill count and self-reported adherence questionnaire to ensure a more realistic result. <sup><xref rid="B42" ref-type="bibr">42</xref></sup> </p>
      <p>Regarding anticoagulation control, a highly reliable method for estimating the stability of warfarin therapy over time is the TTR. The TTR is a measure of the quality of anticoagulation with warfarin that represents the time (in percentage) in which the INR remains within the desirable range. <sup><xref rid="B43" ref-type="bibr">43</xref></sup> We observed that the TTR value was 16.0% below the recommended minimum, resulting in increased risk of thromboembolic and bleeding events. However, given the precariousness of anticoagulation management in the city, we believe the actual results may be even worse than the data presented in this study. Due to the low frequency of patients in consultations, the number of INR measurements was reduced and the interval between these measurements was greater than recommended. Therefore, these factors may have led to an overestimation of the TTR. In addition, the TTR results were not determined based on the total sample (n = 162), as 28 patients had no recorded INR values, and 17 had only one recorded INR value. Therefore, it was not possible to perform TTR calculation for these 45 patients. Although our results showed no significant association when comparing different TTR ranges with inadequate health literacy and insufficient knowledge about oral anticoagulation, we believe these parameters had an influence on the low TTR value observed.</p>
      <p>Another significant point to be considered is the high complexity of the pharmacotherapy observed through the MRCI. Warfarin is known for its high dose-response rate variability, especially when given in combination with certain medications. In their meta-analysis, Wang et al. (2021) demonstrated a clinically relevant increase in the risk of bleeding with the concomitant administration of warfarin with drugs belonging to the most diverse therapeutic classes, such as non-steroidal anti-inflammatory drugs (OR = 1.83; 95% CI 1.29 to 2 .59), antimicrobials (OR = 1.63; 95% CI 1.45 to 1.83), selective serotonin reuptake inhibitors (OR = 1.62; 95% CI 1.42 to 1.85), antiplatelet drugs (OR = 1.74; 95% CI 1.56 to 1.94), loop diuretics (OR = 1.92; 95% CI 1.29 to 2.86), among others. <sup><xref rid="B44" ref-type="bibr">44</xref></sup> Additionally, we can infer that a high complexity of pharmacotherapy combined with low health literacy contributes to a decrease in adherence, although this parameter was not adequately detected in the study due to the low accuracy of the MAT questionnaire. According to Alves-Concei&#231;&#227;o et al. (2018), the high complexity of pharmacotherapy can result in outcomes such as hospitalization and even hospital readmission. Therefore, the high complexity of pharmacotherapy generates great concern, since its consequences may be related to at least 4 deaths observed during the study period. <sup><xref rid="B13" ref-type="bibr">13</xref></sup> </p>
      <p>Regarding limitations of the present study, we could not access the causes of death to verify which ones were related to anticoagulation. Another important limitation refers to the lack of relevant information in the medical records. For a considerable percentage of patients (13.6%), the reason for anticoagulation and the planned duration of anticoagulation required were not recorded, and the patients were not aware of them. As for some indications that anticoagulation may be discontinued, the possibility that a number of these patients will not need to continue taking anticoagulants is a cause for concern. The absence of CHA <sub>2</sub> DS <sub>2</sub> -VASc and HAS-BLED scores in medical records was also alarming. This is definitely a point for improvement, which may be related to weaknesses linked to the organization of the health system. We tried to raise some hypotheses about the lack of adequate follow-up of patients using warfarin: high turnover of professionals and lack of basic training in anticoagulation control, deficit of knowledge and organization of the work process, lack of local oral anticoagulation protocol in the municipality, and lack of opportunities for continuing education.</p>
      <p>We believe that the reality observed in Divin&#243;polis applies to other Brazilian cities, as well as other low- and middle-income countries. The present study highlights a social problem that can be addressed by future intervention studies and competent authorities. Despite the decreasing popularity of warfarin with evidence of non-inferiority or superiority of efficacy compared to DOACs, with decreased bleeding rates, <sup><xref rid="B45" ref-type="bibr">45</xref></sup> it is important to highlight that our findings are also important for DOACs in clinical practice. Although this study focused on patients using warfarin, we believe that a similar scenario can also be observed in primary care patients using DOACs, mainly in low- and middle-income countries. Taking into consideration that there is no method to monitor the anticoagulant effect of DOACs <sup><xref rid="B46" ref-type="bibr">46</xref></sup> and the lack of monitoring is, in fact, a great advantage of these drugs, the detection of drug non-adherence can be impaired. In addition, the impact of missing doses is greater than that of warfarin, due to the shorter half-life of these drugs. <sup><xref rid="B47" ref-type="bibr">47</xref></sup> Therefore, knowledge of the patient's profile is also extremely important for successful treatment with these drugs.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusion</title>
      <p>This study demonstrated remarkably low health literacy and insufficient knowledge about warfarin therapy in a vulnerable population assisted by primary care. The lack of essential information in medical records related to indication of anticoagulation, time required, and thromboembolic and hemorrhagic risk is alarming. These data have great importance to the decision-making process and are essential for developing strategies regarding improvement of the management of patients who are taking anticoagulants. To summarize, since warfarin presents complex drug and food interactions, its use requires special attention from both patients and the health care system.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation>1. Fernandes CJ, Alves JL Jr, Gavilanes F, Prada LF, Morinaga LK, Souza R. New Anticoagulants for the Treatment of Venous Thromboembolism. J Bras Pneumol. 2016;42(2):146-54. doi: 10.1590/S1806-37562016042020068.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fernandes</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Alves</surname>
              <given-names>JL</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Gavilanes</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Prada</surname>
              <given-names>LF</given-names>
            </name>
            <name>
              <surname>Morinaga</surname>
              <given-names>LK</given-names>
            </name>
            <name>
              <surname>Souza</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>New Anticoagulants for the Treatment of Venous Thromboembolism</article-title>
          <source>J Bras Pneumol</source>
          <year>2016</year>
          <volume>42</volume>
          <issue>2</issue>
          <fpage>146</fpage>
          <lpage>154</lpage>
          <pub-id pub-id-type="doi">10.1590/S1806-37562016042020068.</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation>2. Shehab A, Elnour AA, Bhagavathula AS, Erkekoglu P, Hamad F, Al Nuaimi S, et al. Novel Oral Anticoagulants and the 73rd Anniversary of Historical Warfarin. J Saudi Heart Assoc. 2016;28(1):31-45. doi: 10.1016/j.jsha.2015.05.003.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shehab</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Elnour</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Bhagavathula</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Erkekoglu</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hamad</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Al Nuaimi</surname>
              <given-names>S</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Novel Oral Anticoagulants and the 73rd Anniversary of Historical Warfarin</article-title>
          <source>J Saudi Heart Assoc</source>
          <year>2016</year>
          <volume>28</volume>
          <issue>1</issue>
          <fpage>31</fpage>
          <lpage>45</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jsha.2015.05.003.</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation>3. Stambler B, Scazzuso F. Targeting Stroke Risk and Improving Outcomes in Patients with Atrial Fibrillation in Latin America. Sao Paulo Med J. 2016;134(6):534-42. doi: 10.1590/1516-3180.2015.0222110716.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stambler</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Scazzuso</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Targeting Stroke Risk and Improving Outcomes in Patients with Atrial Fibrillation in Latin America</article-title>
          <source>Sao Paulo Med J</source>
          <year>2016</year>
          <volume>134</volume>
          <issue>6</issue>
          <fpage>534</fpage>
          <lpage>542</lpage>
          <pub-id pub-id-type="doi">10.1590/1516-3180.2015.0222110716.</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation>4. Massaro AR, Lip GYH. Stroke Prevention in Atrial Fibrillation: Focus on Latin America. Arq Bras Cardiol. 2016;107(6):576-89. doi: 10.5935/abc.20160116.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Massaro</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Lip</surname>
              <given-names>GYH</given-names>
            </name>
          </person-group>
          <article-title>Stroke Prevention in Atrial Fibrillation: Focus on Latin America</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2016</year>
          <volume>107</volume>
          <issue>6</issue>
          <fpage>576</fpage>
          <lpage>589</lpage>
          <pub-id pub-id-type="doi">10.5935/abc.20160116.</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation>5. Marcolino MS, Polanczyk CA, Bovendorp AC, Marques NS, Silva LA, Turquia CP, et al. Economic Evaluation of the New Oral Anticoagulants for the Prevention of Thromboembolic Events: A Cost-Minimization Analysis. Sao Paulo Med J. 2016;134(4):322-9. doi: 10.1590/1516-3180.2016.0019260216.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marcolino</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Polanczyk</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Bovendorp</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Marques</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Turquia</surname>
              <given-names>CP</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Economic Evaluation of the New Oral Anticoagulants for the Prevention of Thromboembolic Events: A Cost-Minimization Analysis</article-title>
          <source>Sao Paulo Med J</source>
          <year>2016</year>
          <volume>134</volume>
          <issue>4</issue>
          <fpage>322</fpage>
          <lpage>329</lpage>
          <pub-id pub-id-type="doi">10.1590/1516-3180.2016.0019260216.</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation>6. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran Versus Warfarin in Patients with Mechanical Heart Valves. N Engl J Med. 2013;369(13):1206-14. doi: 10.1056/NEJMoa1300615.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eikelboom</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Connolly</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Brueckmann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Granger</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Kappetein</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Mack</surname>
              <given-names>MJ</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Dabigatran Versus Warfarin in Patients with Mechanical Heart Valves</article-title>
          <source>N Engl J Med</source>
          <year>2013</year>
          <volume>369</volume>
          <issue>13</issue>
          <fpage>1206</fpage>
          <lpage>1214</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1300615.</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation>7. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. N Engl J Med. 2013;369(9):799-808. doi: 10.1056/NEJMoa1302507.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Agnelli</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Buller</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Curto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gallus</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>M</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Oral Apixaban for the Treatment of Acute Venous Thromboembolism</article-title>
          <source>N Engl J Med</source>
          <year>2013</year>
          <volume>369</volume>
          <issue>9</issue>
          <fpage>799</fpage>
          <lpage>808</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1302507.</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation>8. Marcatto LR, Sacilotto L, Darrieux FC, Hachul DT, Scanavacca MI, Krieger JE, et al. Age is Associated with Time in Therapeutic Range for Warfarin Therapy in Patients with Atrial Fibrillation. Oncotarget. 2016;7(34):54194-9. doi: 10.18632/oncotarget.10944.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marcatto</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Sacilotto</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Darrieux</surname>
              <given-names>FC</given-names>
            </name>
            <name>
              <surname>Hachul</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Scanavacca</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Krieger</surname>
              <given-names>JE</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Age is Associated with Time in Therapeutic Range for Warfarin Therapy in Patients with Atrial Fibrillation</article-title>
          <source>Oncotarget</source>
          <year>2016</year>
          <volume>7</volume>
          <issue>34</issue>
          <fpage>54194</fpage>
          <lpage>54199</lpage>
          <pub-id pub-id-type="doi">10.18632/oncotarget.10944.</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation>9. Praxedes MFS, Vianna MS, Sousa WJFN, Bartolazzi F, Ara&#250;jo VE, Martins MAP. Instruments for the Assessment of Patient Adherence to Oral Anticoagulation with Warfarin Protocol for a Systematic Review. Medicine. 2019;98(42):e17323. doi: 10.1097/MD.0000000000017323.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Praxedes</surname>
              <given-names>MFS</given-names>
            </name>
            <name>
              <surname>Vianna</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Sousa</surname>
              <given-names>WJFN</given-names>
            </name>
            <name>
              <surname>Bartolazzi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ara&#250;jo</surname>
              <given-names>VE</given-names>
            </name>
            <name>
              <surname>Martins</surname>
              <given-names>MAP</given-names>
            </name>
          </person-group>
          <article-title>Instruments for the Assessment of Patient Adherence to Oral Anticoagulation with Warfarin Protocol for a Systematic Review</article-title>
          <source>Medicine</source>
          <year>2019</year>
          <volume>98</volume>
          <issue>42</issue>
          <elocation-id>e17323</elocation-id>
          <pub-id pub-id-type="doi">10.1097/MD.0000000000017323.</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation>10. Winans AR, Rudd KM, Triller D. Assessing Anticoagulation Knowledge in Patients New to Warfarin Therapy. Ann Pharmacother. 2010;44(7-8):1152-7. doi: 10.1345/aph.1P092.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Winans</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Rudd</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Triller</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Assessing Anticoagulation Knowledge in Patients New to Warfarin Therapy</article-title>
          <source>Ann Pharmacother</source>
          <year>2010</year>
          <volume>44</volume>
          <season>7-8</season>
          <fpage>1152</fpage>
          <lpage>1157</lpage>
          <pub-id pub-id-type="doi">10.1345/aph.1P092.</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation>11. Kimmel SE, Chen Z, Price M, Parker CS, Metlay JP, Christie JD, et al. The Influence of Patient Adherence on Anticoagulation Control with Warfarin: Results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med. 2007;167(3):229-35. doi: 10.1001/archinte.167.3.229.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kimmel</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Price</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Parker</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Metlay</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Christie</surname>
              <given-names>JD</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>The Influence of Patient Adherence on Anticoagulation Control with Warfarin: Results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study</article-title>
          <source>Arch Intern Med</source>
          <year>2007</year>
          <volume>167</volume>
          <issue>3</issue>
          <fpage>229</fpage>
          <lpage>235</lpage>
          <pub-id pub-id-type="doi">10.1001/archinte.167.3.229.</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation>12. Kim MM, Metlay J, Cohen A, Feldman H, Hennessy S, Kimmel S, et al. Hospitalization Costs Associated with Warfarin-Related Bleeding Events Among Older Community-Dwelling Adults. Pharmacoepidemiol Drug Saf. 2010;19(7):731-6. doi: 10.1002/pds.1953.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Metlay</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hennessy</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kimmel</surname>
              <given-names>S</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Hospitalization Costs Associated with Warfarin-Related Bleeding Events Among Older Community-Dwelling Adults</article-title>
          <source>Pharmacoepidemiol Drug Saf</source>
          <year>2010</year>
          <volume>19</volume>
          <issue>7</issue>
          <fpage>731</fpage>
          <lpage>736</lpage>
          <pub-id pub-id-type="doi">10.1002/pds.1953.</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <mixed-citation>13. Alves-Concei&#231;&#227;o V, Rocha KSS, Silva FVN, Silva ROS, Silva DTD, Lyra-Jr DP. Medication Regimen Complexity Measured by MRCI: A Systematic Review to Identify Health Outcomes. Ann Pharmacother. 2018;52(11):1117-1134. doi: 10.1177/1060028018773691.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alves-Concei&#231;&#227;o</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Rocha</surname>
              <given-names>KSS</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>FVN</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>ROS</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>DTD</given-names>
            </name>
            <name>
              <surname>Lyra-Jr</surname>
              <given-names>DP</given-names>
            </name>
          </person-group>
          <article-title>Medication Regimen Complexity Measured by MRCI: A Systematic Review to Identify Health Outcomes</article-title>
          <source>Ann Pharmacother</source>
          <year>2018</year>
          <volume>52</volume>
          <issue>11</issue>
          <fpage>1117</fpage>
          <lpage>1134</lpage>
          <pub-id pub-id-type="doi">10.1177/1060028018773691.</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <mixed-citation>14. Oramasionwu CU, Bailey SC, Duffey KE, Shilliday BB, Brown LC, Denslow SA, et al. The Association of Health Literacy with Time in Therapeutic Range for Patients on Warfarin Therapy. J Health Commun. 2014;19(Suppl 2):19-28. doi: 10.1080/10810730.2014.934934.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oramasionwu</surname>
              <given-names>CU</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Duffey</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Shilliday</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Denslow</surname>
              <given-names>SA</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>The Association of Health Literacy with Time in Therapeutic Range for Patients on Warfarin Therapy</article-title>
          <source>J Health Commun</source>
          <year>2014</year>
          <volume>19</volume>
          <supplement>Suppl 2</supplement>
          <fpage>19</fpage>
          <lpage>28</lpage>
          <pub-id pub-id-type="doi">10.1080/10810730.2014.934934.</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <mixed-citation>15. Cabellos-Garc&#237;a AC, Mart&#237;nez-Sabater A, Castro-S&#225;nchez E, Kangasniemi M, Ju&#225;rez-Vela R, Gea-Caballero V. Relation between Health Literacy, Self-Care and Adherence to Treatment with Oral Anticoagulants in Adults: A Narrative Systematic Review. BMC Public Health. 2018;18(1):1157. doi: 10.1186/s12889-018-6070-9.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cabellos-Garc&#237;a</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Mart&#237;nez-Sabater</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Castro-S&#225;nchez</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kangasniemi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ju&#225;rez-Vela</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gea-Caballero</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Relation between Health Literacy, Self-Care and Adherence to Treatment with Oral Anticoagulants in Adults: A Narrative Systematic Review</article-title>
          <source>BMC Public Health</source>
          <year>2018</year>
          <volume>18</volume>
          <issue>1</issue>
          <size units="pages">1157</size>
          <pub-id pub-id-type="doi">10.1186/s12889-018-6070-9.</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <mixed-citation>16. Li X, Sun S, Wang Q, Chen B, Zhao Z, Xu X. Assessment of Patients' Warfarin Knowledge and Anticoagulation Control at a Joint Physician- and Pharmacist-Managed Clinic in China. Patient Prefer Adherence. 2018;12:783-91. doi: 10.2147/PPA.S156734.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>Assessment of Patients' Warfarin Knowledge and Anticoagulation Control at a Joint Physician- and Pharmacist-Managed Clinic in China</article-title>
          <source>Patient Prefer Adherence</source>
          <year>2018</year>
          <volume>12</volume>
          <fpage>783</fpage>
          <lpage>791</lpage>
          <pub-id pub-id-type="doi">10.2147/PPA.S156734.</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <mixed-citation>17. Costa JMD, Marcolino MS, Torres HC, Resende RE, Souza RP, Barbosa HC, et al. Protocol of a Clinical Trial Study Involving Educational Intervention in Patients Treated with Warfarin. Medicine. 2019;98(22):e15829. doi: 10.1097/MD.0000000000015829.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Costa</surname>
              <given-names>JMD</given-names>
            </name>
            <name>
              <surname>Marcolino</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Torres</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Resende</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Souza</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Barbosa</surname>
              <given-names>HC</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Protocol of a Clinical Trial Study Involving Educational Intervention in Patients Treated with Warfarin</article-title>
          <source>Medicine</source>
          <year>2019</year>
          <volume>98</volume>
          <issue>22</issue>
          <elocation-id>e15829</elocation-id>
          <pub-id pub-id-type="doi">10.1097/MD.0000000000015829.</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <mixed-citation>18. Instituto Brasileiro de Geografia e Estat&#237;stica [Internet]. Divin&#243;polis. Rio de Janeiro: IBGE; 2021 [cited 2021 Aug 25]. Available from: <ext-link ext-link-type="uri" xlink:href="https://cidades.ibge.gov.br/brasil/mg/divinopolis/panorama">https://cidades.ibge.gov.br/brasil/mg/divinopolis/panorama</ext-link> .</mixed-citation>
        <element-citation publication-type="webpage">
          <person-group person-group-type="author">
            <collab>Instituto Brasileiro de Geografia e Estat&#237;stica</collab>
          </person-group>
          <comment>Internet</comment>
          <source>Divin&#243;polis</source>
          <publisher-loc>Rio de Janeiro</publisher-loc>
          <publisher-name>IBGE</publisher-name>
          <year>2021</year>
          <date-in-citation content-type="cited-date">cited 2021 Aug 25</date-in-citation>
          <comment>
            <ext-link ext-link-type="uri" xlink:href="https://cidades.ibge.gov.br/brasil/mg/divinopolis/panorama">https://cidades.ibge.gov.br/brasil/mg/divinopolis/panorama</ext-link>
          </comment>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <mixed-citation>19. Praxedes MFDS, Abreu MHNG, Ribeiro DD, Marcolino MS, Paiva SM, Martins MAP. Cross-Cultural Adaptation of the Oral Anticoagulation Knowledge Test to the Brazilian Portuguese. Cien Saude Colet. 2017;22(5):1615-29. doi: 10.1590/1413-81232017225.17782015.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Praxedes</surname>
              <given-names>MFDS</given-names>
            </name>
            <name>
              <surname>Abreu</surname>
              <given-names>MHNG</given-names>
            </name>
            <name>
              <surname>Ribeiro</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Marcolino</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Paiva</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Martins</surname>
              <given-names>MAP</given-names>
            </name>
          </person-group>
          <article-title>Cross-Cultural Adaptation of the Oral Anticoagulation Knowledge Test to the Brazilian Portuguese</article-title>
          <source>Cien Saude Colet</source>
          <year>2017</year>
          <volume>22</volume>
          <issue>5</issue>
          <fpage>1615</fpage>
          <lpage>1629</lpage>
          <pub-id pub-id-type="doi">10.1590/1413-81232017225.17782015.</pub-id>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <mixed-citation>20. Carvalho ARS, Dantas RA, Pelegrino FM, Corbi IS. Adaptation and Validation of an Oral Anticoagulation Measurement of Treatment Adherence Instrument. Rev Lat Am Enfermagem. 2010;18(3):301-8. doi: 10.1590/s0104-11692010000300002.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carvalho</surname>
              <given-names>ARS</given-names>
            </name>
            <name>
              <surname>Dantas</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Pelegrino</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Corbi</surname>
              <given-names>IS</given-names>
            </name>
          </person-group>
          <article-title>Adaptation and Validation of an Oral Anticoagulation Measurement of Treatment Adherence Instrument</article-title>
          <source>Rev Lat Am Enfermagem</source>
          <year>2010</year>
          <volume>18</volume>
          <issue>3</issue>
          <fpage>301</fpage>
          <lpage>308</lpage>
          <pub-id pub-id-type="doi">10.1590/s0104-11692010000300002.</pub-id>
        </element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <mixed-citation>21. Apolinario D, Braga RC, Magaldi RM, Busse AL, Campora F, Brucki S, et al. Short Assessment of Health Literacy for Portuguese-Speaking Adults. Rev Saude Publica. 2012;46(4):702-11. doi: 10.1590/s0034-89102012005000047.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Apolinario</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Braga</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Magaldi</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Busse</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Campora</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Brucki</surname>
              <given-names>S</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Short Assessment of Health Literacy for Portuguese-Speaking Adults</article-title>
          <source>Rev Saude Publica</source>
          <year>2012</year>
          <volume>46</volume>
          <issue>4</issue>
          <fpage>702</fpage>
          <lpage>711</lpage>
          <pub-id pub-id-type="doi">10.1590/s0034-89102012005000047.</pub-id>
        </element-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <mixed-citation>22. Melchiors AC, Correr CJ, Fern&#225;ndez-Llimos F. Translation and Validation Into Portuguese Language of the Medication Regimen Complexity Index. Arq Bras Cardiol. 2007;89(4):210-8. doi: 10.1590/s0066-782x2007001600001.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Melchiors</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Correr</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Fern&#225;ndez-Llimos</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Translation and Validation Into Portuguese Language of the Medication Regimen Complexity Index</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2007</year>
          <volume>89</volume>
          <issue>4</issue>
          <fpage>210</fpage>
          <lpage>218</lpage>
          <pub-id pub-id-type="doi">10.1590/s0066-782x2007001600001.</pub-id>
        </element-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <mixed-citation>23. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr&#246;m-Lundqvist C, et al. 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Developed with the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hindricks</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Potpara</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Dagres</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Arbelo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bax</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Blomstr&#246;m-Lundqvist</surname>
              <given-names>C</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Developed with the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC</article-title>
          <source>Eur Heart J</source>
          <year>2021</year>
          <volume>42</volume>
          <issue>5</issue>
          <fpage>373</fpage>
          <lpage>498</lpage>
          <pub-id pub-id-type="doi">10.1093/eurheartj/ehaa612.</pub-id>
        </element-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <mixed-citation>24. Ferreira JM, Galato D, Melo AC. Medication Regimen Complexity in Adults and the Elderly in a Primary Healthcare Setting: Determination of High and Low Complexities. Pharm Pract. 2015;13(4):659. doi: 10.18549/PharmPract.2015.04.659.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferreira</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Galato</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Melo</surname>
              <given-names>AC</given-names>
            </name>
          </person-group>
          <article-title>Medication Regimen Complexity in Adults and the Elderly in a Primary Healthcare Setting: Determination of High and Low Complexities</article-title>
          <source>Pharm Pract</source>
          <year>2015</year>
          <volume>13</volume>
          <issue>4</issue>
          <size units="pages">659</size>
          <pub-id pub-id-type="doi">10.18549/PharmPract.2015.04.659.</pub-id>
        </element-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <mixed-citation>25. A Reiffel J. Time to Revisit the Time in the Therapeutic Range. J Atr Fibrillation. 2017;9(5):1569. doi: 10.4022/jafib.1569.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>A Reiffel</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Time to Revisit the Time in the Therapeutic Range</article-title>
          <source>J Atr Fibrillation</source>
          <year>2017</year>
          <volume>9</volume>
          <issue>5</issue>
          <size units="pages">1569</size>
          <pub-id pub-id-type="doi">10.4022/jafib.1569.</pub-id>
        </element-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <mixed-citation>26. McDonald M, Shenkman LJ. Health Literacy and Health Outcomes of Adults in the United States: Implications for Providers. Internet J Allied Health Sci Pract. 2018;16(4):2. doi: 10.46743/1540-580X/2018.1689.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McDonald</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shenkman</surname>
              <given-names>LJ</given-names>
            </name>
          </person-group>
          <article-title>Health Literacy and Health Outcomes of Adults in the United States: Implications for Providers</article-title>
          <source>Internet J Allied Health Sci Pract</source>
          <year>2018</year>
          <volume>16</volume>
          <issue>4</issue>
          <size units="pages">2</size>
          <pub-id pub-id-type="doi">10.46743/1540-580X/2018.1689.</pub-id>
        </element-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <mixed-citation>27. Dewalt DA, Berkman ND, Sheridan S, Lohr KN, Pignone MP. Literacy and Health Outcomes: A Systematic Review of the Literature. J Gen Intern Med. 2004;19(12):1228-39. doi: 10.1111/j.1525-1497.2004.40153.x.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dewalt</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Berkman</surname>
              <given-names>ND</given-names>
            </name>
            <name>
              <surname>Sheridan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lohr</surname>
              <given-names>KN</given-names>
            </name>
            <name>
              <surname>Pignone</surname>
              <given-names>MP</given-names>
            </name>
          </person-group>
          <article-title>Literacy and Health Outcomes: A Systematic Review of the Literature</article-title>
          <source>J Gen Intern Med</source>
          <year>2004</year>
          <volume>19</volume>
          <issue>12</issue>
          <fpage>1228</fpage>
          <lpage>1239</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1525-1497.2004.40153.x.</pub-id>
        </element-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <mixed-citation>28. Cabellos-Garc&#237;a AC, Mart&#237;nez-Sabater A, D&#237;az-Herrera M&#193;, Gea-Caballero V, Castro-S&#225;nchez E. Health Literacy of Patients on Oral Anticoagulation Treatment- Individual and Social Determinants and Effect on Health and Treatment Outcomes. BMC Public Health. 2021;21(1):1363. doi: 10.1186/s12889-021-11259-w.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cabellos-Garc&#237;a</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Mart&#237;nez-Sabater</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>D&#237;az-Herrera</surname>
              <given-names>M&#193;</given-names>
            </name>
            <name>
              <surname>Gea-Caballero</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Castro-S&#225;nchez</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Health Literacy of Patients on Oral Anticoagulation Treatment- Individual and Social Determinants and Effect on Health and Treatment Outcomes</article-title>
          <source>BMC Public Health</source>
          <year>2021</year>
          <volume>21</volume>
          <issue>1</issue>
          <size units="pages">1363</size>
          <pub-id pub-id-type="doi">10.1186/s12889-021-11259-w.</pub-id>
        </element-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <mixed-citation>29. Oramasionwu CU, Bailey SC, Duffey KE, Shilliday BB, Brown LC, Denslow SA, et al. The Association of Health Literacy with Time in Therapeutic Range for Patients on Warfarin Therapy. J Health Commun. 2014;19(Suppl 2):19-28. doi: 10.1080/10810730.2014.934934.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oramasionwu</surname>
              <given-names>CU</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Duffey</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Shilliday</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Denslow</surname>
              <given-names>SA</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>The Association of Health Literacy with Time in Therapeutic Range for Patients on Warfarin Therapy</article-title>
          <source>J Health Commun</source>
          <year>2014</year>
          <volume>19</volume>
          <supplement>Suppl 2</supplement>
          <fpage>19</fpage>
          <lpage>28</lpage>
          <pub-id pub-id-type="doi">10.1080/10810730.2014.934934.</pub-id>
        </element-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <mixed-citation>30. Martins MAP, Costa JM, Mambrini JVM, Ribeiro ALP, Benjamin EJ, Brant LCC, et al. Health Literacy and Warfarin Therapy at Two Anticoagulation Clinics in Brazil. Heart. 2017;103(14):1089-95. doi: 10.1136/heartjnl-2016-310699.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martins</surname>
              <given-names>MAP</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Mambrini</surname>
              <given-names>JVM</given-names>
            </name>
            <name>
              <surname>Ribeiro</surname>
              <given-names>ALP</given-names>
            </name>
            <name>
              <surname>Benjamin</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Brant</surname>
              <given-names>LCC</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Health Literacy and Warfarin Therapy at Two Anticoagulation Clinics in Brazil</article-title>
          <source>Heart</source>
          <year>2017</year>
          <volume>103</volume>
          <issue>14</issue>
          <fpage>1089</fpage>
          <lpage>1095</lpage>
          <pub-id pub-id-type="doi">10.1136/heartjnl-2016-310699.</pub-id>
        </element-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <mixed-citation>31. Bartolazzi F, Ribeiro ALP, Sousa WJFN, Vianna MS, Silva JLP, Martins MAP. Relationship of Health Literacy and Adherence to Oral Anticoagulation Therapy in Patients with Atrial Fibrillation: A Cross-Sectional Study. J Thromb Thrombolysis. 2021;52(4):1074-80. doi: 10.1007/s11239-021-02432-4.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bartolazzi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ribeiro</surname>
              <given-names>ALP</given-names>
            </name>
            <name>
              <surname>Sousa</surname>
              <given-names>WJFN</given-names>
            </name>
            <name>
              <surname>Vianna</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>JLP</given-names>
            </name>
            <name>
              <surname>Martins</surname>
              <given-names>MAP</given-names>
            </name>
          </person-group>
          <article-title>Relationship of Health Literacy and Adherence to Oral Anticoagulation Therapy in Patients with Atrial Fibrillation: A Cross-Sectional Study</article-title>
          <source>J Thromb Thrombolysis</source>
          <year>2021</year>
          <volume>52</volume>
          <issue>4</issue>
          <fpage>1074</fpage>
          <lpage>1080</lpage>
          <pub-id pub-id-type="doi">10.1007/s11239-021-02432-4.</pub-id>
        </element-citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <mixed-citation>32. Ahmed H, Saddouh EA, Abugrin ME, Ali AMM, Elgdhafi EO, Khaled A, et al. Association between Patients' Knowledge and Adherence to Anticoagulants, and Its Effect on Coagulation Control. Pharmacology. 2021;106(5-6):265-74. doi: 10.1159/000511754.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ahmed</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Saddouh</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Abugrin</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Ali</surname>
              <given-names>AMM</given-names>
            </name>
            <name>
              <surname>Elgdhafi</surname>
              <given-names>EO</given-names>
            </name>
            <name>
              <surname>Khaled</surname>
              <given-names>A</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Association between Patients' Knowledge and Adherence to Anticoagulants, and Its Effect on Coagulation Control</article-title>
          <source>Pharmacology</source>
          <year>2021</year>
          <volume>106</volume>
          <season>5-6</season>
          <fpage>265</fpage>
          <lpage>274</lpage>
          <pub-id pub-id-type="doi">10.1159/000511754.</pub-id>
        </element-citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <mixed-citation>33. Elbur A, Albarraq AA, Maugrabi MM, Alharth SA. Knowledge of, Satisfaction with and Adherence to Oral Anticoagulant Drugs among Patients in King Fasial Hospital; Taif, Kingdom Saudi Arabia. Int J Pharm Sci Rev Res. 2015;31(52):274-80.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elbur</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Albarraq</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Maugrabi</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Alharth</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <article-title>Knowledge of, Satisfaction with and Adherence to Oral Anticoagulant Drugs among Patients in King Fasial Hospital; Taif, Kingdom Saudi Arabia</article-title>
          <source>Int J Pharm Sci Rev Res</source>
          <year>2015</year>
          <volume>31</volume>
          <issue>52</issue>
          <fpage>274</fpage>
          <lpage>280</lpage>
        </element-citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <mixed-citation>34. Fang MC, Machtinger EL, Wang F, Schillinger D. Health Literacy and Anticoagulation-Related Outcomes among Patients Taking Warfarin. J Gen Intern Med. 2006;21(8):841-6. doi: 10.1111/j.1525-1497.2006.00537.x.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fang</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Machtinger</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Schillinger</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Health Literacy and Anticoagulation-Related Outcomes among Patients Taking Warfarin</article-title>
          <source>J Gen Intern Med</source>
          <year>2006</year>
          <volume>21</volume>
          <issue>8</issue>
          <fpage>841</fpage>
          <lpage>846</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1525-1497.2006.00537.x.</pub-id>
        </element-citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <mixed-citation>35. Rolls CA, Obamiro KO, Chalmers L, Bereznicki LRE. The Relationship between Knowledge, Health Literacy, and Adherence among Patients Taking Oral Anticoagulants for Stroke Thromboprophylaxis in Atrial Fibrillation. Cardiovasc Ther. 2017;35(6). doi: 10.1111/1755-5922.12304.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rolls</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Obamiro</surname>
              <given-names>KO</given-names>
            </name>
            <name>
              <surname>Chalmers</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bereznicki</surname>
              <given-names>LRE</given-names>
            </name>
          </person-group>
          <article-title>The Relationship between Knowledge, Health Literacy, and Adherence among Patients Taking Oral Anticoagulants for Stroke Thromboprophylaxis in Atrial Fibrillation</article-title>
          <source>Cardiovasc Ther</source>
          <year>2017</year>
          <volume>35</volume>
          <issue>6</issue>
          <pub-id pub-id-type="doi">10.1111/1755-5922.12304.</pub-id>
        </element-citation>
      </ref>
      <ref id="B36">
        <label>36</label>
        <mixed-citation>36. Tang EO, Lai CS, Lee KK, Wong RS, Cheng G, Chan TY. Relationship between Patients' Warfarin Knowledge and Anticoagulation Control. Ann Pharmacother. 2003;37(1):34-9. doi: 10.1345/aph.1A198.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tang</surname>
              <given-names>EO</given-names>
            </name>
            <name>
              <surname>Lai</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>TY</given-names>
            </name>
          </person-group>
          <article-title>Relationship between Patients' Warfarin Knowledge and Anticoagulation Control</article-title>
          <source>Ann Pharmacother</source>
          <year>2003</year>
          <volume>37</volume>
          <issue>1</issue>
          <fpage>34</fpage>
          <lpage>39</lpage>
          <pub-id pub-id-type="doi">10.1345/aph.1A198.</pub-id>
        </element-citation>
      </ref>
      <ref id="B37">
        <label>37</label>
        <mixed-citation>37. Asadi-Lari M, Tamburini M, Gray D. Patients' Needs, Satisfaction, and Health Related Quality of Life: Towards a Comprehensive Model. Health Qual Life Outcomes. 2004;2:32. doi: 10.1186/1477-7525-2-32.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Asadi-Lari</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tamburini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Patients' Needs, Satisfaction, and Health Related Quality of Life: Towards a Comprehensive Model</article-title>
          <source>Health Qual Life Outcomes</source>
          <year>2004</year>
          <volume>2</volume>
          <size units="pages">32</size>
          <pub-id pub-id-type="doi">10.1186/1477-7525-2-32.</pub-id>
        </element-citation>
      </ref>
      <ref id="B38">
        <label>38</label>
        <mixed-citation>38. ACOG Committee Opinion No. 587: Effective Patient-Physician Communication. Obstet Gynecol. 2014;123(2 Pt 1):389-93. doi: 10.1097/01.AOG.0000443279.14017.12.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>ACOG Committee Opinion</collab>
          </person-group>
          <article-title>No. 587: Effective Patient-Physician Communication</article-title>
          <source>Obstet Gynecol</source>
          <year>2014</year>
          <volume>123</volume>
          <issue>2</issue>
          <comment>Pt 1</comment>
          <fpage>389</fpage>
          <lpage>393</lpage>
          <pub-id pub-id-type="doi">10.1097/01.AOG.0000443279.14017.12.</pub-id>
        </element-citation>
      </ref>
      <ref id="B39">
        <label>39</label>
        <mixed-citation>39. National Health Service [Internet]. Why is shared decision making important? London: NHS; 2022 [cited 2022 Jan 11]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.england.nhs.uk/shared-decision-making/why-is-shared-decision-making-important/">https://www.england.nhs.uk/shared-decision-making/why-is-shared-decision-making-important/</ext-link> .</mixed-citation>
        <element-citation publication-type="webpage">
          <person-group person-group-type="author">
            <collab>National Health Service</collab>
          </person-group>
          <comment>Internet</comment>
          <source>Why is shared decision making important?</source>
          <publisher-loc>London</publisher-loc>
          <publisher-name>NHS</publisher-name>
          <year>2022</year>
          <date-in-citation content-type="cited-date">cited 2022 Jan 11</date-in-citation>
          <comment>
            <ext-link ext-link-type="uri" xlink:href="https://www.england.nhs.uk/shared-decision-making/why-is-shared-decision-making-important/">https://www.england.nhs.uk/shared-decision-making/why-is-shared-decision-making-important/</ext-link>
          </comment>
        </element-citation>
      </ref>
      <ref id="B40">
        <label>40</label>
        <mixed-citation>40. Machado APMC, Santos ACG, Carvalho KKA, Godim MPL, Bastos NP, Rocha JVS, et al. Avalia&#231;&#227;o da Ades&#227;o ao Tratamento de Pacientes com Diabetes Mellitus e seus Fatores Associados. REAS. 2019;(19):e565. doi: 10.25248/reas.e565.2019.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Machado</surname>
              <given-names>APMC</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>ACG</given-names>
            </name>
            <name>
              <surname>Carvalho</surname>
              <given-names>KKA</given-names>
            </name>
            <name>
              <surname>Godim</surname>
              <given-names>MPL</given-names>
            </name>
            <name>
              <surname>Bastos</surname>
              <given-names>NP</given-names>
            </name>
            <name>
              <surname>Rocha</surname>
              <given-names>JVS</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Avalia&#231;&#227;o da Ades&#227;o ao Tratamento de Pacientes com Diabetes Mellitus e seus Fatores Associados</article-title>
          <source>REAS</source>
          <year>2019</year>
          <issue>19</issue>
          <elocation-id>e565</elocation-id>
          <pub-id pub-id-type="doi">10.25248/reas.e565.2019.</pub-id>
        </element-citation>
      </ref>
      <ref id="B41">
        <label>41</label>
        <mixed-citation>41. McCambridge J, Witton J, Elbourne DR. Systematic Review of the Hawthorne Effect: New Concepts are Needed to Study Research Participation Effects. J Clin Epidemiol. 2014;67(3):267-77. doi: 10.1016/j.jclinepi.2013.08.015.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McCambridge</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Witton</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Elbourne</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>Systematic Review of the Hawthorne Effect: New Concepts are Needed to Study Research Participation Effects</article-title>
          <source>J Clin Epidemiol</source>
          <year>2014</year>
          <volume>67</volume>
          <issue>3</issue>
          <fpage>267</fpage>
          <lpage>277</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jclinepi.2013.08.015.</pub-id>
        </element-citation>
      </ref>
      <ref id="B42">
        <label>42</label>
        <mixed-citation>42. Mansour SN, Monteiro CN, Luiz OC. Ades&#227;o ao Tratamento Farmacol&#243;gico de Pacientes Hipertensos entre Participantes do Programa Rem&#233;dio em Casa. Epidemio Serv Sa&#250;de. 2021;25(3):647-54. doi: 10.5123/S1679-49742016000300021.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mansour</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Monteiro</surname>
              <given-names>CN</given-names>
            </name>
            <name>
              <surname>Luiz</surname>
              <given-names>OC</given-names>
            </name>
          </person-group>
          <article-title>Ades&#227;o ao Tratamento Farmacol&#243;gico de Pacientes Hipertensos entre Participantes do Programa Rem&#233;dio em Casa</article-title>
          <source>Epidemio Serv Sa&#250;de</source>
          <year>2021</year>
          <volume>25</volume>
          <issue>3</issue>
          <fpage>647</fpage>
          <lpage>654</lpage>
          <pub-id pub-id-type="doi">10.5123/S1679-49742016000300021.</pub-id>
        </element-citation>
      </ref>
      <ref id="B43">
        <label>43</label>
        <mixed-citation>43. Gateman D, Trojnar ME, Agarwal G. Time in Therapeutic Range: Warfarin Anticoagulation for Atrial Fibrillation in a Community-Based Practice. Can Fam Physician. 2017;63(10):e425-e431.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gateman</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Trojnar</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Agarwal</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Time in Therapeutic Range: Warfarin Anticoagulation for Atrial Fibrillation in a Community-Based Practice</article-title>
          <source>Can Fam Physician</source>
          <year>2017</year>
          <volume>63</volume>
          <issue>10</issue>
          <fpage>e425</fpage>
          <lpage>e431</lpage>
        </element-citation>
      </ref>
      <ref id="B44">
        <label>44</label>
        <mixed-citation>44. Wang M, Zeraatkar D, Obeda M, Lee M, Garcia C, Nguyen L, et al. Drug-Drug Interactions with Warfarin: A Systematic Review and Meta-Analysis. Br J Clin Pharmacol. 2021;87(11):4051-100. doi: 10.1111/bcp.14833.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zeraatkar</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Obeda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>L</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Drug-Drug Interactions with Warfarin: A Systematic Review and Meta-Analysis</article-title>
          <source>Br J Clin Pharmacol</source>
          <year>2021</year>
          <volume>87</volume>
          <issue>11</issue>
          <fpage>4051</fpage>
          <lpage>4100</lpage>
          <pub-id pub-id-type="doi">10.1111/bcp.14833.</pub-id>
        </element-citation>
      </ref>
      <ref id="B45">
        <label>45</label>
        <mixed-citation>45. Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and Benefits of Direct Oral Anticoagulants Versus Warfarin in a Real World Setting: Cohort Study in Primary Care. BMJ. 2018;362:k2505. doi: 10.1136/bmj.k2505.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vinogradova</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Coupland</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hippisley-Cox</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Risks and Benefits of Direct Oral Anticoagulants Versus Warfarin in a Real World Setting: Cohort Study in Primary Care</article-title>
          <source>BMJ</source>
          <year>2018</year>
          <volume>362</volume>
          <size units="pages">k2505</size>
          <pub-id pub-id-type="doi">10.1136/bmj.k2505.</pub-id>
        </element-citation>
      </ref>
      <ref id="B46">
        <label>46</label>
        <mixed-citation>46. Chen A, Stecker E, A Warden B. Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. J Am Heart Assoc. 2020;9(13):e017559. doi: 10.1161/JAHA.120.017559.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Stecker</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>A Warden</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges</article-title>
          <source>J Am Heart Assoc</source>
          <year>2020</year>
          <volume>9</volume>
          <issue>13</issue>
          <elocation-id>e017559</elocation-id>
          <pub-id pub-id-type="doi">10.1161/JAHA.120.017559.</pub-id>
        </element-citation>
      </ref>
      <ref id="B47">
        <label>47</label>
        <mixed-citation>47. Oxfordshire Clinical Commissioning Group Primary Care Prescriber Decision Support for Direct Oral Anticoagulants &#8216;DOACs&#8217; for Stroke Prevention in Atrial Fibrillation [Internet]. England: NHS; 2019 [cited 2022 Jan 11]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.oxfordshireccg.nhs.uk/professional-resources/documents/clinical-guidelines/cardiovascular/prescriber-decision-support-for-DOACs-in-atrial-fibrillation.pdf">https://www.oxfordshireccg.nhs.uk/professional-resources/documents/clinical-guidelines/cardiovascular/prescriber-decision-support-for-DOACs-in-atrial-fibrillation.pdf</ext-link> .</mixed-citation>
        <element-citation publication-type="webpage">
          <source>Oxfordshire Clinical Commissioning Group Primary Care Prescriber Decision Support for Direct Oral Anticoagulants &#8216;DOACs&#8217; for Stroke Prevention in Atrial Fibrillation</source>
          <comment>Internet</comment>
          <publisher-loc>England</publisher-loc>
          <publisher-name>NHS</publisher-name>
          <year>2019</year>
          <date-in-citation content-type="cited-date">cited 2022 Jan 11</date-in-citation>
          <comment>
            <ext-link ext-link-type="uri" xlink:href="https://www.oxfordshireccg.nhs.uk/professional-resources/documents/clinical-guidelines/cardiovascular/prescriber-decision-support-for-DOACs-in-atrial-fibrillation.pdf">https://www.oxfordshireccg.nhs.uk/professional-resources/documents/clinical-guidelines/cardiovascular/prescriber-decision-support-for-DOACs-in-atrial-fibrillation.pdf</ext-link>
          </comment>
        </element-citation>
      </ref>
      <ref id="B48">
        <label>48</label>
        <mixed-citation>48. Instituto de Pesquisa Econ&#244;mica Aplicada. Macroeconomic. Minimum wage. Frenquency: Monthly from 1940.07 to 2021.12 [Internet]. Bras&#237;lia: IPEA; 2022 [cited 2022 Jan 11]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ipeadata.gov.br">http://www.ipeadata.gov.br</ext-link> .</mixed-citation>
        <element-citation publication-type="webpage">
          <person-group person-group-type="author">
            <collab>Instituto de Pesquisa Econ&#244;mica Aplicada</collab>
          </person-group>
          <source>Macroeconomic. Minimum wage. Frenquency: Monthly from 1940.07 to 2021.12</source>
          <comment>Internet</comment>
          <publisher-loc>Bras&#237;lia</publisher-loc>
          <publisher-name>IPEA</publisher-name>
          <year>2022</year>
          <date-in-citation content-type="cited-date">cited 2022 Jan 11</date-in-citation>
          <comment>
            <ext-link ext-link-type="uri" xlink:href="http://www.ipeadata.gov.br">http://www.ipeadata.gov.br</ext-link>
          </comment>
        </element-citation>
      </ref>
      <ref id="B49">
        <label>49</label>
        <mixed-citation>49. Instituto de Pesquisa Aplicada. Macroeconomic. Exchange rate - Brazilian real (R$) / US dollar (US$) - selling - average. Frenquency: Annual from 1889 to 2020 [Internet]. Bras&#237;lia: IPEA; 2022 [cited 2022 Jan 11]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ipeadata.gov.br">http://www.ipeadata.gov.br</ext-link> .</mixed-citation>
        <element-citation publication-type="webpage">
          <person-group person-group-type="author">
            <collab>Instituto de Pesquisa Aplicada</collab>
          </person-group>
          <source>Macroeconomic. Exchange rate - Brazilian real (R$) / US dollar (US$) - selling - average. Frenquency: Annual from 1889 to 2020</source>
          <comment>Internet</comment>
          <publisher-loc>Bras&#237;lia</publisher-loc>
          <publisher-name>IPEA</publisher-name>
          <year>2022</year>
          <date-in-citation content-type="cited-date">cited 2022 Jan 11</date-in-citation>
          <comment>
            <ext-link ext-link-type="uri" xlink:href="http://www.ipeadata.gov.br">http://www.ipeadata.gov.br</ext-link>
          </comment>
        </element-citation>
      </ref>
    </ref-list>
    <fn-group>
      <fn fn-type="other">
        <p>Disclosures: None.</p>
      </fn>
      <fn fn-type="other">
        <p>Role of the funder/sponsor</p>
        <p>The sponsors had no role in study design; data collection, management, analysis, and interpretation; writing the manuscript; and decision to submit it for publication. MSM had full access to all the data in the study and had responsibility for the decision to submit for publication.</p>
      </fn>
      <fn fn-type="other">
        <p>Transparency declaration</p>
        <p>The lead authors (MSM and ALR) affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned (and, if relevant, registered) have been explained.</p>
      </fn>
      <fn fn-type="other">
        <p>Study Association</p>
        <p>This study is not associated with any thesis or dissertation work.</p>
      </fn>
      <fn fn-type="other">
        <p>Ethics Approval and Consent to Participate</p>
        <p>This article does not contain any studies with human participants or animals performed by any of the authors.</p>
      </fn>
    </fn-group>
    <fn-group>
      <fn fn-type="financial-disclosure" id="fn11">
        <p>Sources of Funding: This study was supported by the National Institute of Science and Technology for Health Technology Assessment (IATS/CNPq, grant 465518/2014-1) and National Council for Scientific and Technological Development (CNPq, grant 428433/2016-2) and Minas Gerais State Agency for Research and Development (FAPEMIG, grant RED-00081-16). Ribeiro ALP was supported in part by the Brazilian research agencies CNPq (Bolsa de Produtividade em Pesquisa 310790/2021-2) and FAPEMIG (Programa Pesquisador Mineiro PPM-00428-17 and Rede de Teleassist&#234;ncia de Minas Gerais RED-00081-16), and Marcolino MS was supported in part by CNPq (Bolsa de Produtividade em Pesquisa 310561/2021-3). Ribeiro ALP and Marcolino MS are members of the National Institute of Science and Technology for Health Technology. S&#225; LC received a scholarship from CNPq (IATS/CNPq, grant 103315/2021-7), Pedroso TM received scholarships from Pr&#243;-Reitoria de Extens&#227;o from Federal University of Minas Gerais (PROEX UFMG) and Oliveira JAQ received doctoral grant (number 88887.142558/2017-00) from the Coordena&#231;&#227;o de Aperfei&#231;oamento de Pessoal de N&#237;vel Superior - Brasil (CAPES) &#8211; Finance Code 001, as part of the IATS/CNPq.</p>
      </fn>
    </fn-group>
  </back>
</article>
